1. The Key Laboratory of Geriatrics, Beijing Hospital & Beijing Institute of Geriatrics, Ministry of Health, Beijing, 100730, China.
Theranostics. 2011;1:395-402. doi: 10.7150/thno/v01p0395. Epub 2011 Dec 12.
Vascular endothelial growth factor (VEGF), an important angiogenic factor that is able to stimulate the proliferation and migration of endothelial cells, is the best-studied hallmark of angiogenesis. Neovascularization is a major cause of age-related macular degeneration (AMD) which is a leading cause of blindness in the elderly population. Specific molecular inhibitors of VEGF have been proved to be useful in the treatment of AMD. Ranibizumab and Bevacizumab are structurally similar to anti-VEGF drugs in the treatment of AMD. Many studies have indicated that Ranibizumab and Bevacizumab are of roughly equal short-term efficacy and safety, Bevacizumab is an attractive alternative to Ranibizumab due to its lower cost. However, only Ranibizumab has received Food and Drug Administration (FDA) approval for the treatment of macular degeneration. More multicenter clinical trials are required to compare the relative efficacy and safety of these two drugs and some progress has been achieved. This review discusses the clinical effectiveness, safety, cost and other practical implications of Ranibizumab and Bevacizumab.
血管内皮生长因子（VEGF）是一种重要的血管生成因子，能够刺激内皮细胞的增殖和迁移，是血管生成的研究热点。新生血管是年龄相关性黄斑变性（AMD）的主要原因，AMD 是老年人致盲的主要原因。VEGF 的特异性分子抑制剂已被证明对 AMD 的治疗有效。雷珠单抗和贝伐单抗在治疗 AMD 时与抗 VEGF 药物在结构上相似。许多研究表明，雷珠单抗和贝伐单抗在短期疗效和安全性方面大致相当，由于贝伐单抗价格较低，因此它是雷珠单抗的一个有吸引力的替代品。然而，只有雷珠单抗获得了食品和药物管理局（FDA）批准用于治疗黄斑变性。需要更多的多中心临床试验来比较这两种药物的相对疗效和安全性，并且已经取得了一些进展。本文综述了雷珠单抗和贝伐单抗的临床疗效、安全性、成本和其他实际意义。
